# reload+after+2024-01-21 13:47:55.219962
address1§343 Allerton Avenue
city§South San Francisco
state§CA
zip§94080
country§United States
phone§650 577 3600
fax§888 482 2602
website§https://www.vistagen.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
fullTimeEmployees§33
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Shawn K. Singh J.D.', 'age': 60, 'title': 'CEO & Director', 'yearBorn': 1963, 'fiscalYear': 2023, 'totalPay': 600000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Reid G. Adler Esq., J.D.', 'age': 69, 'title': 'Chief Corporate Development & Legal Officer', 'yearBorn': 1954, 'fiscalYear': 2023, 'totalPay': 371875, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Cynthia Lynn Anderson CPA', 'age': 54, 'title': 'Chief Financial Officer', 'yearBorn': 1969, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joshua  Prince M.B.A.', 'age': 53, 'title': 'Chief Operating Officer', 'yearBorn': 1970, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark Adrian McPartland', 'age': 57, 'title': 'Senior Vice President of Investor Relations', 'yearBorn': 1966, 'fiscalYear': 2023, 'totalPay': 300000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Trisha  Fitzmaurice', 'title': 'Senior Vice President of Human Resources', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Allen Easley Cato III, M.D., Ph.D.', 'title': 'Senior Vice President of Development Operations', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mark J. Ginski Ph.D.', 'age': 51, 'title': 'Senior VP and Head of Chemistry, Manufacturing & Controls', 'yearBorn': 1972, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark  Flather', 'title': 'Senior Vice President of Corporate Strategy & Capital Markets', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Erik  Berglund M.D., Ph.D.', 'title': 'Senior VP of Global Regulatory Affairs & Pharmacovigilance', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.745
priceToSalesTrailing12Months§168.03938
currency§USD
dateShortInterest§1702598400
forwardEps§-2.17
exchange§NCM
quoteType§EQUITY
shortName§VistaGen Therapeutics, Inc.
longName§Vistagen Therapeutics, Inc.
firstTradeDateEpochUtc§1308663000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§c6acbc64-ce57-3e37-99eb-7238ee56ebc2
gmtOffSetMilliseconds§-18000000
targetHighPrice§15.0
targetLowPrice§12.0
targetMeanPrice§13.0
targetMedianPrice§12.0
recommendationMean§1.2
recommendationKey§strong_buy
numberOfAnalystOpinions§3
quickRatio§12.926
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
